Vertex Pharmaceuticals (VRTX)
$177.66 0.00 (0.00%)
17:50 EDT VRTX Stock Quote Delayed 15 Minutes
Previous Close $177.66
Market Cap 45.27B
PE Ratio 206.58
Volume (Avg. Vol.)
Day's Range 177.66 - 177.66
52-Week Range 145.37 - 195.81
Dividend & Yield N/A (N/A)
VRTX Stock Predictions, Articles, and Vertex Pharmaceuticals News
- From InvestorPlace
- From the Web
Growth is on a different track now, and here are some great ideas for stocks to buy to ride the momentum.
Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
One of the best mutual funds last year was the T. Rowe Price Health Sciences Fund. Here are 7 healthcare stocks to buy from its holdings.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
Put these fast-growing stocks on your radar, if not in your portfolio, as your best shot at overcoming the market's summertime blues.
The market volatility isn't all bad! Now investors can find stocks to buy at killer entry points --determined by the Street's stop analysts.
These three high-reward stocks, each with their own emerging trend, that have huge upside potential in the transformative years ahead.
These four stocks are among the best U.S. stocks to buy today, as they beat S&P 500 growth rates in the past and should maintain strong growth rates in the years ahead.
One thing is certain, healthcare isn’t going away.
3 Stocks to Watch on Thursday: Mondelez International Inc (MDLZ), Paypal Holdings Inc (PYPL) and Vertex Pharmaceuticals Incorporated (VRTX)
Mondelez (MDLZ) beat earnings expectations, Paypal (PYPL) revenue grew 24% and Vertex Pharmaceuticals' (VRTX) adjusted income up 74%.
Currently, Vertex Pharmaceuticals Inc (NASDAQ:VRTX) has a Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. This represents no change from the previous week and is the same ranking VRTX has had from Portfolio Grader for 4 months.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a member of the 350 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care sector. The market value of VRTX is $35.6 billion which falls in the top 10% of its industry group. The stock's current Portfolio Grader score places it 32 among the 350 companies in this industry group, positioning it among the leaders; in the top quartile of the sector with a ranking of 102 among the 782 companies in the sector, and number 591 in the nearly 5,000 company Portfolio Grader universe.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is ranked as a Buy using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. This represents no change from the previous week and is the same ranking VRTX has had from Portfolio Grader for 4 months.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 781 company GICS Health Care sector. VRTX's market value is $37.2 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for VRTX puts it 60 among the 349 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 158 among the 781 companies in the sector, and number 1,038 in the nearly 5,000 company Portfolio Grader universe.
From Market News Video
The Vertex Pharmaceuticals (NASDAQ:VRTX) Share Price Is Up 161% And Shareholders Are Boasting About It
From Simply Wall St
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It hasn’t been the best quarter for<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/the-vertex-pharmaceuticals-nasdaqvrtx-share-price-is-up-161-and-shareholders-are-boasting-about-it/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!